Activist Radoff-Jumana Group Files Definitive Proxy, Seeks Two Board Seats & Opposes Equity Plan
Summary
Activist investors Bradley L. Radoff and Jumana Capital have filed their definitive proxy statement, urging shareholders to elect their two nominees to Genesco's board and vote against the proposed executive compensation and a new equity incentive plan.
Key Events
-
Proxy Contest Finalized
The Radoff-Jumana Group, holding an 8.7% stake, filed its definitive proxy statement for the July 21, 2026 Annual Meeting, formalizing its challenge to Genesco's current board and management.
-
Board Nominees Proposed
The activist group is seeking to elect two independent nominees, Westervelt T. Ballard, Jr. and Paula J. Poskon, to the nine-member board, targeting two incumbent directors.
-
Opposition to Equity Incentive Plan
The group recommends voting against the proposed Fourth Amended and Restated 2020 Equity Incentive Plan, which would increase shares available for issuance by 1.2 million, representing approximately 10.8% potential dilution.
-
Executive Compensation Vote
The activist group also recommends voting against the non-binding advisory vote on named executive officers' compensation, citing underperformance during CEO Mimi Vaughn's tenure.
Analysis
This definitive proxy statement from the Radoff-Jumana Group marks a critical stage in the ongoing proxy contest, directly challenging Genesco's leadership ahead of the July 21st Annual Meeting. The activist group, holding a significant 8.7% stake, is pushing for substantial changes by seeking to elect two independent directors and opposing key management proposals, including a potentially dilutive equity plan and executive compensation. The outcome of this vote will determine the future composition of Genesco's board and could significantly influence the company's strategic direction, capital allocation, and governance practices.
At the time of this filing, GCO was trading at $36.11 on NYSE in the Trade & Services sector, with a market capitalization of approximately $401M. The 52-week trading range was $19.62 to $43.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.